Targeting Hsp90α and its co‐chaperone and ATPase activator Aha1 with inhibitors, such as KU‐177, reduces tau aggregations in Alzheimer's disease [134, 135]. This evidence concerns the gene HSP90AA1 and Alzheimer disease.